| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3846304 | Advances in Chronic Kidney Disease | 2015 | 9 Pages |
Abstract
The landscape of therapeutic options for hepatitis B and C has changed drastically over the course of 2 decades. There are now novel, effective, well-tolerated, oral antiviral agents being used to successfully control chronic hepatitis B (HBV) infections and cure chronic hepatitis C (HCV) infections. However, patients with CKD were rarely included in the Phase II and III randomized trials for these medications. This paucity of data and the high prevalence of comorbidities associated with CKD pose distinct challenges to physicians treating chronic hepatitis B virus and hepatitis C virus infections in the setting of kidney insufficiency/failure. Thus, this review will attempt to summarize the current data regarding novel antiviral therapies for HBV and HCV in the CKD population.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
Adam E. Mikolajczyk, Andrew I. Aronsohn,